SCHEMBL3306789

SCHEMBL3306789

O=C(OCC(O)CO)C(O)CCCCCCCCCCCCCCCCO

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
KDM4E B2RXH2 1/20 0.45
DUSP3 P51452 1/20 0.45
LMNA P02545 1/20 0.45
DGKA P23743 1/20 0.39
USP2 O75604 3/20 0.34
FAAH O00519 4/20 0.34
GPR84 Q9NQS5 3/20 0.33
ALDH1A1 P00352 2/20 0.33
CYP3A4 P08684 2/20 0.33
MAPT P10636 2/20 0.33
HPGD P15428 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
THRB P10828 1/20 0.33
TP53 P04637 1/20 0.33
MAPK1 P28482 1/20 0.33
FFAR1 O14842 1/20 0.33
PTPN1 P18031 1/20 0.33
ACACB O00763 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3277348 0.91 MEN1 (0.46) MEN1KMT2AKDM4EDUSP3LMNA
Ethylene Glycol SCHEMBL27039396 0.86 KDM4E (0.59) MEN1KMT2AKDM4EDUSP3LMNA
SCHEMBL127957 0.86 KDM4E (0.63) MEN1KMT2AKDM4EDUSP3LMNA
SCHEMBL1123305 0.86 KDM4E (0.63) MEN1KMT2AKDM4EDUSP3LMNA
SCHEMBL1123654 0.86 KDM4E (0.63) MEN1KMT2AKDM4EDUSP3LMNA
SCHEMBL19281558 0.84 KDM4E (0.60) MEN1KMT2AKDM4EDUSP3LMNA
SCHEMBL28984432 0.82 MEN1 (0.42) MEN1KMT2AKDM4EDUSP3LMNA
SCHEMBL39606 0.82 MEN1 (0.42) MEN1KMT2AKDM4EDUSP3LMNA
SCHEMBL28496592 0.82 LMNA (0.46) MEN1KMT2AKDM4EDUSP3LMNA
Sulfuric Acid SCHEMBL28346044 0.80 KDM4E (0.56) MEN1KMT2AKDM4EDUSP3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3558467-B1 STABILIZATION OF COSMETIC COMPOSITIONS COMPRISING FISH OILS AND HYDROXYLATED FATTY ACIDS AND/OR ITS DERIVATIVES UNILEVER IP HOLDINGS B V (NL) 2023-06-07 EP claimed
US-10166235-B2 Kinetin/zeatin topical formulation DOW PHARMACEUTICAL SCIENCES, INC. (US) 2019-01-01 US claimed
US-20180311246-A1 KINETIN/ZEATIN TOPICAL FORMULATION JPMORGAN CHASE BANK, N.A. 2018-11-01 US claimed
US-9925194-B2 Kinetin/zeatin topical formulation DOW PHARMACEUTICAL SCIENCES, INC. (US) 2018-03-27 US claimed
US-20170209453-A1 KINETIN/ZEATIN TOPICAL FORMULATION JPMORGAN CHASE BANK, N.A. 2017-07-27 US claimed
US-9616132-B2 Kinetin/zeatin topical formulation DOW PHARMACEUTICAL SCIENCES, INC. (US) 2017-04-11 US claimed
US-20140271826-A1 KINETIN/ZEATIN TOPICAL FORMULATION DOW PHARMACEUTICAL SCIENCES, INC. (US) 2014-09-18 US claimed
CN-103521952-A Welding-bonding dual-purpose halogen-free electronic addition agent and preparation method thereof WEST ELECTRONIC MATERIALS CO LTD 2014-01-22 CN claimed
US-20250332084-A1 PEPTIDE COMPOSITION AND RESPECTIVE USES UNIVERSIDADE DO MINHO (PT) 2025-10-30 US disclosed
US-20250319008-A1 HAIR COMPOSITIONS USES AND METHODS THEREOF FUNCTION INC (US) 2025-10-16 US disclosed
US-12383484-B2 Peptide composition and respective uses UNIVERSIDADE DO MINHO (PT) 2025-08-12 US disclosed
WO-2025137392-A1 CONDITIONER COMPOSITIONS, CLEANSER COMPOSITIONS AND METHODS OF USING THE SAME K18, INC. (US) 2025-06-26 WO disclosed
EP-4543547-A2 DETOX HAIR AND SCALP CLEANSER COMPOSITION, METHODS AND USES THEREOF K18, Inc. (US) 2025-04-30 EP disclosed
EP-4543406-A1 HAIR CLEANSER COMPOSITION, METHODS AND USES THEREOF K18, Inc. (US) 2025-04-30 EP disclosed
EP-1203141-A1 LINKAGE OF AGENTS TO TISSUE Pericor Science, Inc. (US) 2002-05-08 EP disclosed
WO-2002007707-A2 LINKAGE OF AGENTS USING MICROPARTICLES PERICOR SCIENCE, INC. (US) 2002-01-31 WO disclosed
WO-2001007009-A1 LYSINE OXIDASE LINKAGE OF AGENTS TO TISSUE PERICOR SCIENCE, INC. (US) 2001-02-01 WO disclosed
WO-2001006829-A2 LINKAGE OF AGENTS TO TISSUE PERICOR SCIENCE, INC. (US) 2001-02-01 WO disclosed
EP-0768867-A1 DOSAGE FORM FOR ADMINISTERING DRUG IN LIQUID FORMULATION ALZA CORPORATION (US) 1997-04-23 EP disclosed
WO-1995034285-A1 DOSAGE FORM FOR ADMINISTERING DRUG IN LIQUID FORMULATION ALZA CORPORATION (US) 1995-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250319008-A1 HAIR COMPOSITIONS USES AND METHODS THEREOF CUTA, KRT18, NACA MEN1 3801/4885KMT2A 2443/4885KDM4E 801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.